Deutsche Bank Aktiengesellschaft Reiterates “Buy” Rating for GSK (LON:GSK)

Deutsche Bank Aktiengesellschaft restated their buy rating on shares of GSK (LON:GSKFree Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a GBX 1,950 ($24.78) target price on the stock.

Several other research analysts have also recently issued reports on the company. Shore Capital reaffirmed a buy rating on shares of GSK in a report on Wednesday, June 12th. Barclays reaffirmed an equal weight rating and issued a GBX 1,725 ($21.92) price target on shares of GSK in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. reissued an underweight rating on shares of GSK in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of Hold and a consensus price target of GBX 1,675.63 ($21.29).

Check Out Our Latest Report on GSK

GSK Price Performance

LON GSK opened at GBX 1,599 ($20.32) on Tuesday. The stock has a market capitalization of £65.24 billion, a P/E ratio of 1,466.97, a P/E/G ratio of 1.19 and a beta of 0.27. GSK has a 1 year low of GBX 1,302.60 ($16.55) and a 1 year high of GBX 1,823.50 ($23.17). The business’s fifty day moving average is GBX 1,689.20 and its two-hundred day moving average is GBX 1,625.18. The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87.

GSK Cuts Dividend

The business also recently declared a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be issued a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 0.9%. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is currently 5,504.59%.

Insider Activity

In related news, insider Wendy Becker purchased 446 shares of the stock in a transaction dated Thursday, June 20th. The shares were acquired at an average cost of GBX 1,614 ($20.51) per share, for a total transaction of £7,198.44 ($9,146.68). 1.60% of the stock is currently owned by corporate insiders.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Articles

Analyst Recommendations for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.